XML 96 R82.htm IDEA: XBRL DOCUMENT v3.26.1

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands	1 Months Ended				3 Months Ended			6 Months Ended		12 Months Ended
	Oct. 31, 2025 manufacturer certificate	Jul. 31, 2025	Jun. 30, 2025 USD ($)	Mar. 31, 2025 USD ($)	Jun. 30, 2026 USD ($)	Sep. 30, 2025 USD ($) notice	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Dec. 31, 2017 USD ($)	Jan. 31, 2026 USD ($)	Apr. 07, 2025 period	Feb. 28, 2025	Aug. 31, 2023 USD ($)
Loss Contingencies [Line Items]
Volumes distributed in US market in duration period												12 months
Increasing modestly period | period												2
Agreement period of volumes distributed in market												3 years
Legal settlement					$ 0		$ 0	$ 0	$ 7,000
Number of paragraph certification | certificate	2
Number of generic drug manufacturers | manufacturer	2
GQ Bio Therapeutics GmbH
Loss Contingencies [Line Items]
Percentage of voting interests acquired													81.00%
GQ Bio Therapeutics GmbH | GQ Bio Therapeutics GmbH
Loss Contingencies [Line Items]
Percentage of voting interests acquired													81.00%
Johnson & Johnson MedTech
Loss Contingencies [Line Items]
Mutual termination rights term		1 year
Johnson & Johnson MedTech | ZILRETTA
Loss Contingencies [Line Items]
Option extended term		12 months
GeneQuine | Achievement of Development and Regulatory Milestones | Flexion
Loss Contingencies [Line Items]
Achievement of commercial milestones (up to)										$ 56,000
GeneQuine | Initiation of a Phase 2 Clinical Trial | Flexion
Loss Contingencies [Line Items]
Achievement of commercial milestones (up to)										4,500
GeneQuine | Development and Global Regulatory Approval Milestone Payments | Flexion
Loss Contingencies [Line Items]
Achievement of commercial milestones (up to)										51,500
Baylor College of Medicine (Baylor) | Minimum
Loss Contingencies [Line Items]
Range of milestone payment										100
Baylor College of Medicine (Baylor) | Maximum
Loss Contingencies [Line Items]
Range of milestone payment										$ 600
LG Chem, Partnership Agreement
Loss Contingencies [Line Items]
Upfront payment											$ 2,000
MyoScience Milestone Litigation
Loss Contingencies [Line Items]
Repayments for royalties				$ 5,200					$ 5,200
Research Development Foundation
Loss Contingencies [Line Items]
Repayments for royalties			$ 23,100			$ 23,100
Expect to receive partial summary judgment														$ 23,100
Additional interest payment			$ 5,200			5,200
Payment received						$ 28,300
Number of notices are filed | notice						2

X

- Definition

Represents the amount of milestone payments the Company is entitled to receive based on the terms of the agreement.

+ References

No definition available.

+ Details

Name:	pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum
Namespace Prefix:	pcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Contractual Obligation, Minimum Monthly Commission, Duration

+ References

No definition available.

+ Details

Name:	pcrx_ContractualObligationMinimumMonthlyCommissionDuration
Namespace Prefix:	pcrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Contractual Obligation, Mutual Termination Rights Term

+ References

No definition available.

+ Details

Name:	pcrx_ContractualObligationMutualTerminationRightsTerm
Namespace Prefix:	pcrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Litigation Settlement, Amount Expected To Be Awarded from Other Party

+ References

No definition available.

+ Details

Name:	pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty
Namespace Prefix:	pcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Litigation Settlement, Volume-Limited, Increase Period

+ References

No definition available.

+ Details

Name:	pcrx_LitigationSettlementVolumeLimitedIncreasePeriod
Namespace Prefix:	pcrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Litigation Settlement, Volume-Limited, Maximum Percentage, Period

+ References

No definition available.

+ Details

Name:	pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod
Namespace Prefix:	pcrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Litigation Settlement, Volume-Limited, Number Of Moderate Increase Periods

+ References

No definition available.

+ Details

Name:	pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods
Namespace Prefix:	pcrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Number Of Generic Drug Manufacturers

+ References

No definition available.

+ Details

Name:	pcrx_NumberOfGenericDrugManufacturers
Namespace Prefix:	pcrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number Of Paragraph IV Certifications

+ References

No definition available.

+ Details

Name:	pcrx_NumberOfParagraphIVCertifications
Namespace Prefix:	pcrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Revenue from Contract with Customer, Milestone Payments, Maximum

+ References

No definition available.

+ Details

Name:	pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum
Namespace Prefix:	pcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Percentage of voting equity interest acquired in business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-38

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

+ Details

Name:	us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-11

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount awarded from other party in judgment or settlement of litigation.

+ References

No definition available.

+ Details

Name:	us-gaap_LitigationSettlementAmountAwardedFromOtherParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Interest expense (income) directly attributable to an award in settlement of litigation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(6))
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_LitigationSettlementInterest
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of loss from litigation settlement for amount awarded to other party. Excludes claims within an insurance entity's normal claims settlement process.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

+ Details

Name:	us-gaap_LitigationSettlementLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482645/405-30-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.W.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479583/944-40-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483359/720-20-50-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 27
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482395/460-10-55-27

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of pending claims pertaining to a loss contingency.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

+ Details

Name:	us-gaap_LossContingencyPendingClaimsNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Cash received for the settlement of litigation during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_ProceedsFromLegalSettlements
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=pcrx_GQBioTherapeuticsGmbHMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_OwnershipAxis=pcrx_GQBioTherapeuticsGmbHMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=pcrx_JohnsonJohnsonMedTechMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=pcrx_ZILRETTAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=pcrx_GeneQuineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=pcrx_FlexionTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	pcrx_AchievementOfMilestoneAxis=pcrx_InitiationOfAPhase2ClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	pcrx_AchievementOfMilestoneAxis=pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=pcrx_BaylorCollegeOfMedicineBaylorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=pcrx_LGChemPartnershipAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_LitigationCaseAxis=pcrx_MyoScienceMilestoneLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_LitigationCaseAxis=pcrx_ResearchDevelopmentFoundationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: